Unknown

Dataset Information

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.


ABSTRACT:

Objectives

The efficacy of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, has not previously been evaluated in a population consisting exclusively of patients with early rheumatoid arthritis (RA).

Methods

In a double-blind randomised controlled trial (FUNCTION), 1162 methotrexate (MTX)-naive patients with early progressive RA were randomly assigned (1:1:1:1) to one of four treatment groups: 4 mg/kg TCZ+MTX, 8 mg/kg TCZ+MTX, 8 mg/kg TCZ+placebo and placebo+MTX (comparator group). The primary outcome was remission according to Disease Activity Score using 28 joints (DAS28-erythrocyte sedimentation rate (ESR) <2.6) at week 24. Radiographic and physical function outcomes were also evaluated. We report results through week 52.

Results

The intent-to-treat popul

SUBMITTER: Burmester GR 

PROVIDER: S-EPMC4893095 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature